Article Text

PDF
Fibrinolysis for myocardial infarction: the ISIS-2 and asset trials

Abstract

Last year we reviewed the status of fibrinolytic therapy (thrombolysis) in the early treatment of myocardial infarction (MI).1 Thrombolysis can reopen the occluded coronary artery, reduce infarct size and improve prognosis. It is, therefore, recommended as routine treatment for most patients admitted to hospital early after MI. Two further large studies of intravenous fibrinolytic therapy have recently confirmed this policy. The results also clarify which categories of patient benefit.

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.